Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Morley

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|September 11, 2019
Withdrawal Symptoms From E-Cigarette Abstinence Among Adult Never-Smokers: A Pilot Experimental StudyJohn R Hughes, Erica N Peters, Peter W Callas, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|July 29, 2019
Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers: A Pre-Post Clinical TrialJohn R Hughes, Erica N Peters, Peter W Callas, et al.
Open Forum Infectious Diseases|June 24, 2024
Get2PrEP2-A Provider Messaging Strategy to Improve PrEP Uptake: A Randomized Controlled Quality Improvement ProjectJason Zucker, Delivette Castor, Deborah Theodore, et al.
The Lancet. Haematology|March 31, 2022
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trialDavid I Marks, Laura Clifton-Hadley, Mhairi Copland, et al.
Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|September 11, 2019
Withdrawal Symptoms From E-Cigarette Abstinence Among Adult Never-Smokers: A Pilot Experimental StudyJohn R Hughes, Erica N Peters, Peter W Callas, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|July 29, 2019
Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers: A Pre-Post Clinical TrialJohn R Hughes, Erica N Peters, Peter W Callas, et al.
Open Forum Infectious Diseases|June 24, 2024
Get2PrEP2-A Provider Messaging Strategy to Improve PrEP Uptake: A Randomized Controlled Quality Improvement ProjectJason Zucker, Delivette Castor, Deborah Theodore, et al.
The Lancet. Haematology|March 31, 2022
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trialDavid I Marks, Laura Clifton-Hadley, Mhairi Copland, et al.
Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Pageof 2